{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T21:18:59Z","timestamp":1773955139059,"version":"3.50.1"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2008,3,1]],"date-time":"2008-03-01T00:00:00Z","timestamp":1204329600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clin. Exper.Med."],"published-print":{"date-parts":[[2008,3]]},"DOI":"10.1007\/s10238-008-0150-6","type":"journal-article","created":{"date-parts":[[2008,4,2]],"date-time":"2008-04-02T16:21:25Z","timestamp":1207153285000},"page":"9-15","source":"Crossref","is-referenced-by-count":37,"title":["The value of antinuclear antibodies in primary biliary cirrhosis"],"prefix":"10.1007","volume":"8","author":[{"given":"Lixia","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xinping","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fengchun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2008,4,3]]},"reference":[{"key":"150_CR1","first-page":"387","volume":"46","author":"E. Rubin","year":"1965","unstructured":"Rubin E, Schaffner F, Popper H (1965) Primary biliary cirrhosis. Am J Pathol 46:387\u2013407","journal-title":"Am J Pathol"},{"key":"150_CR2","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1053\/gast.2002.36027","volume":"123","author":"M. Prince","year":"2002","unstructured":"Prince M, Chetwynd A, Newman W et al (2002) Survival and symptoms progression in a geographically based cohort of patients with primary biliary cirrhosis: follow-up to 28 years. Gastroenterology 123:1044\u20131051","journal-title":"Gastroenterology"},{"key":"150_CR3","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/0016-5085(91)80033-6","volume":"100","author":"M.E. Gershwin","year":"1991","unstructured":"Gershwin ME, Mackay IR (1991) Primary biliary cirrhosis: paradigm or paradox for autoimmunity. Gastroenterology 100:822\u2013833","journal-title":"Gastroenterology"},{"key":"150_CR4","doi-asserted-by":"crossref","first-page":"8534","DOI":"10.1056\/NEJM197309272891306","volume":"289","author":"S. Sherlock","year":"1973","unstructured":"Sherlock S, Sheuer PJ (1973) The presentation and diagnosis of 100 patients with primary biliary cirrhosis. N Engl J Med 289:8534","journal-title":"N Engl J Med"},{"key":"150_CR5","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/S0300-5089(21)00118-8","volume":"4","author":"F. Schaffner","year":"1975","unstructured":"Schaffner F (1975) Primary biliary cirrhosis. Clin Gastroenterol 4:351\u2013366","journal-title":"Clin Gastroenterol"},{"key":"150_CR6","first-page":"512","volume":"316","author":"M.M. Kaplan","year":"1987","unstructured":"Kaplan MM (1987) Primary biliary cirrhosis. N Engl J Med 316:512\u2013518","journal-title":"N Engl J Med"},{"key":"150_CR7","doi-asserted-by":"crossref","first-page":"500","DOI":"10.7326\/0003-4819-99-4-500","volume":"99","author":"S.P. James","year":"1993","unstructured":"James SP, Hoofnagle JH, Strober W, Jones EA (1993) NIH conference: primary biliary cirrhosis: a model autoimmune disease. Ann Intern Med 99:500\u2013502","journal-title":"Ann Intern Med"},{"key":"150_CR8","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/0016-5085(80)90571-5","volume":"78","author":"E. Christensen","year":"1980","unstructured":"Christensen E, Crowe J, Doniach D et al (1980) Clinical pattern and course of disease in primary biliary cirrhosis based on an analysis of 236 patients. Gastroenterology 78:236\u2013246","journal-title":"Gastroenterology"},{"key":"150_CR9","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1016\/S0140-6736(65)91372-3","volume":"39","author":"J.G. Walker","year":"1965","unstructured":"Walker JG, Doniach D, Roitt IM, Sherlock S (1965) Serological tests in diagnosis of primary biliary cirrhosis. Lancet 39:827\u2013831","journal-title":"Lancet"},{"key":"150_CR10","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0140-6736(03)13808-1","volume":"362","author":"J.A. Talwalkar","year":"2003","unstructured":"Talwalkar JA, Lindor KD (2003) Primary biliary cirrhosis. Lancet 362:53\u201361","journal-title":"Lancet"},{"key":"150_CR11","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/S1568-9972(03)00013-2","volume":"2","author":"H.J. Worman","year":"2003","unstructured":"Worman HJ, Courvalinc JC (2003) Antinuclear antibodies specific for primary biliary cirrhosis. Autoimmun Rev 2:211\u2013217","journal-title":"Autoimmun Rev"},{"key":"150_CR12","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1746.1998.01553.x","volume":"13","author":"S. Itoh","year":"1998","unstructured":"Itoh S, Ichida T, Yoshida T et al (1998) Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 13:257\u2013265","journal-title":"J Gastroenterol Hepatol"},{"key":"150_CR13","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(00)00040-4","volume":"34","author":"P. Invernizzi","year":"2001","unstructured":"Invernizzi P, Podda M, Battezzati PM et al (2001) Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 34:366\u2013372","journal-title":"J Hepatol"},{"key":"150_CR14","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","volume":"98","author":"P. Muratori","year":"2003","unstructured":"Muratori P, Muratori L, Ferrari R et al (2003) Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98:431\u2013437","journal-title":"Am J Gastroenterol"},{"key":"150_CR15","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/hep.21472","volume":"45","author":"M. Nakamura","year":"2007","unstructured":"Nakamura M, Kondo H, Mori T et al (2007) Anti-gp210 and anti-centromere antibodies are different risk factors for the progression of primary biliary cirrhosis. Hepatology 45:118\u2013127","journal-title":"Hepatology"},{"key":"150_CR16","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1542-3565(04)00465-3","volume":"2","author":"W.-H. Yang","year":"2004","unstructured":"Yang W-H, Yu JH, Nakajima A et al (2004) Do antinuclear antibody in primary biliary cirrhosis patients identify increased risk for liver failure. Clin Gastroenterol Hepatol 2:1116\u20131122","journal-title":"Clin Gastroenterol Hepatol"},{"key":"150_CR17","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1053\/he.2000.5984","volume":"31","author":"E.J. Heathcote","year":"2000","unstructured":"Heathcote EJ (2000) Management of primary biliary cirrhosis. The American Association for the Study of Liver Diseases Practice Guideline. Hepatology 31:1005\u20131013","journal-title":"Hepatology"},{"key":"150_CR18","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/hep.510290301","volume":"29","author":"P. Angulo","year":"1999","unstructured":"Angulo P, Batts KP, Therneau TM et al (1999) Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 29:644\u2013647","journal-title":"Hepatology"},{"key":"150_CR19","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1002\/hep.510290444","volume":"29","author":"C. Degott","year":"1999","unstructured":"Degott C, Zafrani ES, Callard P et al (1999) Histopathological study of primary biliary cirrhosis and the effect of ursodeoxycholic acid treatment on histology progression. Hepatology 29:1007\u20131012","journal-title":"Hepatology"},{"key":"150_CR20","first-page":"1257","volume":"60","author":"P.J. Scheuer","year":"1967","unstructured":"Scheuer PJ (1967) Primary biliary cirrhosis. Proc R Soc Med 60:1257\u20131260","journal-title":"Proc R Soc Med"},{"key":"150_CR21","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1136\/ard.61.6.554","volume":"61","author":"C. Vitali","year":"2002","unstructured":"Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sj\u00f6gren\u2019s syndrome: a revised version of the European criteria proposed by the American-European consensus group. Ann Rheum Dis 61:554\u2013558","journal-title":"Ann Rheum Dis"},{"key":"150_CR22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1055\/s-2005-916321","volume":"25","author":"P. Invernizzi","year":"2005","unstructured":"Invernizzi P, Selmi C, Ranftler C et al (2005) Antinuclear antibodies in primary biliary cirrhosis. Semin Liver Dis 25:298\u2013310","journal-title":"Semin Liver Dis"},{"key":"150_CR23","doi-asserted-by":"crossref","first-page":"1135","DOI":"10.1002\/hep.21172","volume":"43","author":"J. Wesierska-Gadek","year":"2006","unstructured":"Wesierska-Gadek J, Penner E, Battezzati PM et al (2006) Correlation of initial autoantibody profile and clinical outcome in primary biliary cirrhosis. Hepatology 43:1135\u20131144","journal-title":"Hepatology"},{"key":"150_CR24","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.jhep.2004.11.016","volume":"42","author":"M. Nakamura","year":"2005","unstructured":"Nakamura M, Shimizu-Yoshida Y, Takii Y et al (2005) Antibody titer to gp210-C terminal peptide as a clinical parameter for monitoring primary biliary cirrhosis. J Hepatol 42:386\u2013392","journal-title":"J Hepatol"},{"key":"150_CR25","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1111\/j.1440-1746.1998.01553.x","volume":"13","author":"S. Itoh","year":"1998","unstructured":"Itoh S, Ichida T, Yoshida T et al (1998) Autoantibodies against a 210 kDa glycoprotein of the nuclear pore complex as a prognostic marker in patients with primary biliary cirrhosis. J Gastroenterol Hepatol 13:257\u2013265","journal-title":"J Gastroenterol Hepatol"},{"key":"150_CR26","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/S0168-8278(00)00040-4","volume":"34","author":"P. Invernizzi","year":"2001","unstructured":"Invernizzi P, Podda M, Battezzati PM et al (2001) Autoantibodies against nuclear pore complexes are associated with more active and severe liver disease in primary biliary cirrhosis. J Hepatol 34:366\u2013372","journal-title":"J Hepatol"},{"key":"150_CR27","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1111\/j.1572-0241.2003.07257.x","volume":"98","author":"P. Muratori","year":"2003","unstructured":"Muratori P, Muratori L, Ferrari R et al (2003) Characterization and clinical impact of antinuclear antibodies in primary biliary cirrhosis. Am J Gastroenterol 98:431\u2013437","journal-title":"Am J Gastroenterol"},{"key":"150_CR28","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jaut.2005.10.007","volume":"26","author":"M. Nakamura","year":"2006","unstructured":"Nakamura M, Takii Y, Ito M et al (2006) Increased expression of nuclear envelope gp210 antigen in small bile ducts in primary biliary cirrhosis. J Autoimmun 26:138\u2013145","journal-title":"J Autoimmun"},{"key":"150_CR29","first-page":"1488","volume":"32","author":"S. Miyawaki","year":"2005","unstructured":"Miyawaki S, Asanuma H, Nishiyama S, Yoshinaga Y (2005) Clinical and serological heterogeneity in patients with anti-centromere antibodies. J Rheumatol 32:1488\u20131494","journal-title":"J Rheumatol"},{"key":"150_CR30","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1136\/ard.52.8.586","volume":"52","author":"S.L. Lee","year":"1993","unstructured":"Lee SL, Tsay GJ, Tsai RT (1993) Subjects with no apparent connective tissue disease. Ann Rheum Dis 52:586\u2013589","journal-title":"Ann Rheum Dis"},{"key":"150_CR31","first-page":"612","volume":"23","author":"E.M. Tan","year":"1980","unstructured":"Tan EM, Rodana GP, Garcia I et al (1980) Diversity of antinuclear antibodies in progressive systemic sclerosis: anti-centromere antibody and its relationship to CREST syndrome. Arthritis Rheum 23:612\u2013614","journal-title":"Arthritis Rheum"},{"key":"150_CR32","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1111\/j.1440-1746.1995.tb01597.x","volume":"10","author":"S. Parveen","year":"1995","unstructured":"Parveen S, Morshed SA, Nishiok M (1995) High prevalence of antibodies to recombinant CENP-B in primary biliary cirrhosis: nuclear immunofluorescence patterns and ELISA reactivities. J Gastroenterol Hepatol 10:438\u2013445","journal-title":"J Gastroenterol Hepatol"},{"key":"150_CR33","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1136\/ard.41.6.612","volume":"41","author":"R.M. Bernstein","year":"1982","unstructured":"Bernstein RM, Callender ME, Neuberger JM et al (1982) Anti-centromere antibodies in primary biliary cirrhosis. Ann Rheum Dis 41:612\u2013614","journal-title":"Ann Rheum Dis"},{"key":"150_CR34","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1002\/art.1780260714","volume":"26","author":"D. Makinen","year":"1983","unstructured":"Makinen D, Fritzler M, Davis P, Sherlock S (1983) Anti-centromere antibodies in primary biliary cirrhosis. Arthritis Rheum 26:914\u2013917","journal-title":"Arthritis Rheum"},{"key":"150_CR35","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1136\/gut.2005.075002","volume":"55","author":"C. Rigamonti","year":"2006","unstructured":"Rigamonti C, Shand LM, Feudjo M et al (2006) Clinical features and prognosis of primary biliary cirrhosis associated with systems sclerosis. Gut 55:388\u2013394","journal-title":"Gut"},{"key":"150_CR36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1034\/j.1399-3038.2000.00066.x","volume":"11","author":"E. Hossny","year":"2000","unstructured":"Hossny E, Abdul HH, Mabrouk R (2000) Anti-centromere antibodies as a marker of Raynaud\u2019s phenomenon in pediatric rheumatologic diseases. Pediatric Allergy Immunol 11:250\u2013255","journal-title":"Pediatric Allergy Immunol"},{"key":"150_CR37","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/hep.1840110504","volume":"11","author":"E.V. Tsianos","year":"1990","unstructured":"Tsianos EV, Hoofnagle JH, Fox PC et al (1990) Sj\u00f6gren\u2019s syndrome in patients with primary biliary cirrhosis. Hepatology 11:730\u2013734","journal-title":"Hepatology"},{"key":"150_CR38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/j.1365-2796.1991.tb00470.x","volume":"230","author":"P. Uddenfeldt","year":"1991","unstructured":"Uddenfeldt P, Danielsson A, Forssell A et al (1991) Features of Sj\u00f6gren\u2019s syndrome in patients with primary biliary cirrhosis. J Intern Med 230:443\u2013448","journal-title":"J Intern Med"},{"key":"150_CR39","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1136\/ard.46.4.286","volume":"46","author":"J. Coll","year":"1987","unstructured":"Coll J, Rives A, Gri\u00f1\u00f3 MC et al (1987) Prevalence of Sj\u00f6gren\u2019s syndrome in autoimmune diseases. Ann Rheum Dis 46:286\u2013289","journal-title":"Ann Rheum Dis"},{"key":"150_CR40","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1007\/s00296-004-0568-4","volume":"26","author":"T.C. Hsu","year":"2006","unstructured":"Hsu TC, Chang CH, Lin MC et al (2006) Anti-CENP-H antibodies in patients with Sj\u00f6gren\u2019s syndrome. Rheumatol Int 26:298\u2013303","journal-title":"Rheumatol Int"},{"key":"150_CR41","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/ard.58.5.320","volume":"58","author":"A. Hida","year":"1999","unstructured":"Hida A, Kawabe Y, Kawakami A et al (1999) HTLV-I associated Sj\u00f6gren\u2019s syndrome is aetiologically distinct from anti-centromere antibodies positive Sj\u00f6gren\u2019s syndrome. Ann Rheum Dis 58:320\u2013322","journal-title":"Ann Rheum Dis"},{"key":"150_CR42","first-page":"2238","volume":"28","author":"K. Katano","year":"2001","unstructured":"Katano K, Kawano M, Koni I et al (2001) Clinical and laboratory features of anti-centromere antibody positive primary Sj\u00f6gren\u2019s syndrome. J Rheumatol 28:2238\u20132244","journal-title":"J Rheumatol"}],"container-title":["Clinical and Experimental Medicine"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-008-0150-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10238-008-0150-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10238-008-0150-6","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,7]],"date-time":"2021-09-07T02:11:27Z","timestamp":1630980687000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10238-008-0150-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,3]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2008,3]]}},"alternative-id":["150"],"URL":"https:\/\/doi.org\/10.1007\/s10238-008-0150-6","relation":{},"ISSN":["1591-8890","1591-9528"],"issn-type":[{"value":"1591-8890","type":"print"},{"value":"1591-9528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2008,3]]}}}